Antibody drug conjugates in gynaecological cancers: navigating between opportunities and challenges
Esteban Ciliberti, Marta Nerone, Vincenza Ricco, Hui-Ming Lin, Frederik Marmé, Cristiana Sessa, Isabelle Ray Coquard, Kathleen N. Moore, Ilaria Colombo · 2026
Read Antibody drug conjugates in gynaecological cancers: navigating between opportunities and challenges by Esteban Ciliberti, Marta Nerone, Vincenza Ricco, Hui-Ming Lin, Frederik Marmé, Cristiana Sessa, Isabelle Ray Coquard, Kathleen N. Moore, Ilaria Colombo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13420614.txt.
Description
Esteban Ciliberti and colleagues review antibody-drug conjugates in gynecological cancers, drugs that ride a targeting antibody straight into tumor cells before releasing a toxic payload. More than 210 such drugs sit in clinical testing in the count the authors cite, and fifteen gained approval across cancers in the past decade. Gynecological tumors were slower to benefit than breast or lung cancers.
The review draws on database searches, major cancer conference reports, and trial registries to map where each drug stands. Cancer-specific surface anchors make the tailored strikes possible, and biomarker testing decides who should receive them. Strong phase three results could reset standard care for several of these cancers. The authors balance that promise against toxicity and cost challenges that clinics already feel.
Catalog record
| CREATOR | Esteban Ciliberti, Marta Nerone, Vincenza Ricco, Hui-Ming Lin, Frederik Marmé, Cristiana Sessa, Isabelle Ray Coquard, Kathleen N. Moore, Ilaria Colombo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 100590 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |